Patients with a history of a different malignancy are excluded, unless the disease has not progressed for >= 2 years
Previous therapy with anthracyclines or taxanes for any malignancy
Patient must not have a concurrent active malignancy for which they are receiving treatment
Prior or current invasive malignancy with current evidence of active disease within the past 3 years
No other active malignancy that the investigator determines would interfere with the treatment and safety analysis
Patients with a history of any malignancy are ineligible
Active second malignancy requiring treatment or that would interfere with assessment of response of the lymphoma per investigator’s discretion
Leptomeningeal disease as the only manifestation of the current malignancy
Prior malignancy other than acute leukemia is allowed, provided it is in remission and there is no plan to treat the malignancy at the time of registration
Individuals with a history of a malignancy (other than multiple myeloma) are ineligible except for the following circumstances; individuals with a history of other malignancies are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy
Patients with an active second malignancy (other than non-melanoma skin cancer or cervical carcinoma in situ) are NOT eligible for participation; patients who have a history of malignancy are not considered to have a currently active malignancy if they have completed therapy and are now considered by their physician to be at < 30% risk for relapse
Other invasive malignancy within 2 years.
Participants with other active malignancy requiring concurrent intervention
Prior malignancy
Other active malignancy requiring concurrent intervention
History of prior malignancy, except (Criteria a through f):
Any known additional malignancy that is progressing or required active treatment in the last 3 years
History of other malignancy within 2 years prior to screening
History of malignancy other than gastric or gastroesophageal junction carcinoma within 2 years prior to screening, with the exception of those with a negligible risk of metastasis or death;
History of other malignancy that could affect compliance with the protocol or interpretation of results
Subjects with other active malignancy requiring concurrent intervention
Other active malignancy that is progressing, requires concurrent intervention, and/or could be mistaken for the malignancy under study during disease assessments
Active malignancy (other than BRAF V600 mutation-negative melanoma) or malignancy within 3 years
Participants with other active malignancy in the past 3 years excluding in situ tumors
History of other malignancy that could affect compliance with the protocol or interpretation of results
Second malignancy (solid or hematologic) within the past 3 years except locally curable cancers that have been apparently cured
History of other malignancy that could affect compliance with the protocol or interpretation of results
Phase 2 only: second malignancy within the last 3 years.
Known history of another primary malignancy that has not been in remission for ?1 year
Any other current or previous malignancy within 3 years except protocol allowed malignancies
History of other malignancy unless the subject has been disease-free for at least 3 years
Subject must have histological or cytological evidence of a solid malignancy
Patients being actively treated for a secondary malignancy
Patients with a currently active second malignancy other than non-melanoma skin cancer. Patients are not considered to have a currently active malignancy if they have completed necessary therapy and are considered by their physician to be at <30% risk of relapse at time of assessment.
Confirmed diagnosis of a relapsed or refractory malignancy in 1 of 2 treatment groups:
Active secondary malignancy
Other malignancy within 2 years prior to entry into the study, except for those treated with surgical therapy only (e.g., localized low-grade cervical or prostate cancers).
Participants with an active second malignancy
History of prior malignancy unless disease free for > or equal to 12 months or considered surgically cured.
Secondary malignancy.
Other active malignancy requiring therapy such as radiation, chemotherapy, or immunotherapy.
Diagnosis of another malignancy within 2 years before the first dose of cabozantinib, except for superficial skin cancers, or localized, low grade tumors deemed cured and not treated with systemic therapy
Diagnosis of another malignancy within 2 years before planned first dose of study drug, except for superficial skin cancers, or localized, low grade tumors
Past or present malignancy within the last 5 years.
Active second malignancy.
Concurrent active malignancy requiring immediate therapy
A patient with a known other malignancy is eligible if there is a negligible risk for disease progression or death within one year, there is no active ongoing treatment for this malignancy, and the malignancy and/or any anticipated future treatments would not interfere with protocol-mandated evaluations at 1 year
Patients with a prior malignancy will NOT be eligible for participation aside from the following exception:\r\n* Patients who have had any curatively treated invasive malignancy and have been disease free without treatment for 1 year prior to study entry ARE eligible for participation
BRAF V600 mutation-positive malignancy
Currently, no active second malignancy other than non-melanoma skin cancer; note: patients are not considered to have a \current active\ malignancy if they have completed anti-cancer therapy and are considered by their physicians to have a less than 30% chance of relapse
Pts receiving active treatment or intervention for any other malignancy or pts who, at the Investigator's discretion, may require active treatment or intervention for any other malignancy within 8 months of starting study treatment.
Diagnosis of another malignancy within 2 years before the first dose of study treatment, except for superficial skin cancers, or localized, low grade tumors deemed cured and not treated with systemic therapy
History of another malignancy within 3 years of the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy.
Active malignancy other than the one for which AB-110 transplant is being performed within 12 months of enrollment.
Individuals with a history of different malignancy are ineligible except for the following circumstances. Individuals with a history of other malignancies are eligible if they have been disease-free for at least 3 years or are deemed by the principal investigator to be at low risk for recurrence of that malignancy
Participants with other active malignancy requiring concurrent intervention
Have a primary CNS malignancy (eg, GBM).
Has a known additional malignancy that is progressing or requires active treatment within the past 5 years.
Participants with any other active malignancy requiring concurrent intervention
History of malignancy other than MM within the past 3 years
Active cerebral/meningeal disease related to the underlying malignancy
Other active malignancy that warrants systemic therapy
Previous therapy with anthracyclines or taxanes for any malignancy.
Previous therapy with anthracyclines or taxanes for any malignancy
History of other malignancy within 5 years prior to screening, with the exception of those with a negligible risk of metastasis or death
Participants with progressive systemic malignancy
Subjects with a \currently active\ second malignancy other than non-melanoma skin or superficial urothelial cancers are not eligible; subjects are not considered to have a \currently active\ malignancy if they have completed therapy and are now considered without evidence of disease for 2 years prior to cycle 1 day 1
Individuals with a history of different malignancy are ineligible except for the following circumstances; individuals with a history of other malignancies are eligible if they have been disease-free for at least 3 years or are deemed by the investigator to be at low risk for recurrence of that malignancy
A prior or concurrent metastatic second malignancy within 3 years, even if it does not require active therapy; for example, patients with concomitant indolent B-cell malignancies will not be eligible; patients with a prior resected in-situ or stage I malignancy felt to be cured will be eligible
Has a history of a second malignancy, unless potentially curative treatment has been completed, with no evidence of malignancy for 2 years.
Uncontrolled concurrent malignancy (early stage is allowed if not requiring active therapy or intervention)
Prior or concurrent malignancy with known RAS mutation
Participants with relapsed primary malignancy, or who have been treated for relapse after the alloSCT was performed
Steroid refractory cGvHD occurring after a non-scheduled donor lymphocyte infusion (DLI) administered for preemptive treatment of malignancy recurrence. Participants who have received a scheduled DLI as part of their transplant procedure and not for management of malignancy relapse are eligible
Patients with suspected non-gynecologic malignancy, such as gastrointestinal
Subject has any other active malignancy besides the tumor under study within 3 years prior to Screening. Subject has uncontrolled intercurrent illness
Presence of an active hematological malignancy.
Presence of concurrent non-solid malignancy
History of malignancy other than B-NHL within the past 3 years with the exception of:
Have a second primary malignancy that in the judgment of the investigator or Lilly may affect the interpretation of results.
Patients with a “currently active” second malignancy other than non-melanoma skin cancers; patients are not considered to have a “currently active” malignancy if they have completed therapy and are free of disease for >= 3 years
Part B: Must have a type of malignancy that is being studied.
No other active malignancy
History of other active malignancy within past 2 years.
Evidence of relapse or progression of hematologic malignancy at the time of study enrollment.
Persistence/relapse at the time of study entry of the primary malignancy for which the transplant was performed, or any other active malignancy; patients with a history of relapsed malignancy who have achieved a remission at the time of evaluation for study participation will not be excluded
Patients with concurrent malignancy except for nonmelanoma skin lesions
Participants with an active second malignancy (other than non-melanoma skin cancer or cervical carcinoma in situ). Participants who have a history of malignancy are not considered to have an active malignancy if they have completed therapy and are considered by their treating physician to be at <= 30 percent (%) risk for relapse
Active concurrent malignancy requiring active therapy
Are currently receiving other medications intended for the treatment of their malignancy.
Patients must NOT have an active malignancy other than CD19+ leukemia
Prior invasive malignancy of other histology currently requiring treatment
Have a second primary malignancy that in the judgment of the investigator and sponsor may affect the interpretation of results (Part B only)
Previous or concurrent additional malignancy
In patients with a prior history of invasive malignancy, less than five years in complete remission
Previous malignancy is not an exclusion provided that the other malignancy is considered under control, patient is not on concomitant anti-cancer drug therapy, and target lesions from melanoma are clearly defined for response assessment
Advanced measurable malignancy
Patient is ? 5 years free of another primary malignancy, except: a) if the other malignancy is basal cell carcinoma or cervical carcinoma in situ or b) if the other primary malignancy is not considered clinically significant and is requiring no active intervention
Previous malignancy is not an exclusion provided that the other malignancy is considered under control, patient is not on concomitant anti-cancer drug therapy, and target lesions from melanoma are clearly defined for response assessment
No evidence of malignancy at the time of enrollment
Prior other malignancy within 2 years (except for in situ disease, which is permissible).
No evidence of an active malignancy that would limit the patient’s survival to less than 2 years. (If there is any question, the principal investigator [PI] can make a decision).
Patient must not have a concurrent active malignancy for which they are receiving treatment
Patients with a concurrent active malignancy under treatment.
Any active malignancy other than DLBCL
Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured
Known additional malignancy that is active and/or progressive requiring treatment; subjects with other malignancies that have been definitively treated and who have been rendered disease free will be eligible.
Participants with other active malignancy requiring concurrent intervention
Other active malignancy
History of another malignancy except for:
Active second malignancy, i.e. patient known to have potentially fatal cancer present for which he/she may be (but not necessarily) currently receiving treatment; patients with a history of malignancy that has been completely treated, with no evidence of that cancer currently, are permitted to enroll in the trial provided all chemotherapy for prior malignancy was completed > 12 months prior and/or bone marrow transplant > 2 years prior
Participants must not have a known additional malignancy that could confuse analysis of on-study treatment; inclusion of all study participants with more than one malignancy must be discussed and approved by the principal investigator (PI)
T-cell malignancy
Other active malignancy requiring concurrent intervention
Known additional malignancy that is progressing or requires active treatment within 3 years of start of study drug.
Presence of any other concurrent active malignancy
Has a known additional malignancy that is progressing or requires active treatment
COHORT 3: ENDOMETRIAL CANCER: Patients with a history of another invasive malignancy within the last 3 years
Active malignancy (other than melanoma) or a prior malignancy within the past 3 years
Prior therapy for glioblastoma or other invasive malignancy
Other malignancy requiring treatment in the prior 2 years
No active secondary malignancy
Cold agglutinin syndrome secondary to infection, rheumatologic disease, or active hematologic malignancy
Second primary malignancy within the last 5 years, unless treated definitively and with low risk of recurrence in the judgment of the treating investigator
History of malignancy other than NSCLC within 2 years prior to screening
Participants must not have other active malignancy requiring concurrent intervention
Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention, other than non-melanoma skin cancer and carcinoma in situ of the cervix should not be enrolled; patients are not considered to have a “currently active” malignancy if they have completed therapy for a prior malignancy, are disease free from a prior malignancy for >= 5 yrs and are considered by their physician to be less than 30% risk of relapse
Subjects must NOT have an active malignancy other than CD19+CD22+ leukemia
Patients with concurrent second malignancy. Persons with previous malignancies effectively treated and not requiring treatment for >24 months are eligible, provided there is unambiguous documentation that current local recurrence or metastatic site represents recurrence of the primary breast malignancy.
No other active malignancy
Evidence of another malignancy, exclusive of a skin cancer that requires only local treatment
Individuals with a history of different malignancy are ineligible except for the following circumstances; individuals with a history of other malignancies are eligible if they have been disease-free for at least 3 years or are deemed by the investigator to be at low risk for recurrence of that malignancy
Has had known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years of study entry.
Active concurrent second malignancy.
Known additional malignancy that is progressing or requires active treatment
Have a history of another primary malignancy, with the exception of:
Active second malignancy, i.e. patient known to have potentially fatal hematologic malignancy or another solid primary tumor present for which he/she may be (but not necessarily) currently receiving treatment; patients with a history of malignancy that has been completely treated, with no evidence of that cancer currently, are permitted to enroll in the trial provided treatment was completed > 2 years prior; patients with early-stage skin cancers and prostate cancer under surveillance with non-rising prostate specific antigen (PSA) are eligible
Other active malignancy requiring concurrent intervention.
Has history of other active malignancy within 3 years prior to enrollment, except:
Known additional malignancy that requires active systemic treatment
Subjects must NOT have an active malignancy other than CD22+ leukemia
Has a known additional malignancy that is progressing or requires active treatment
Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy.
No other active malignancy
Patient has malignancy or life-threatening systemic disease or a history of advanced, serious, life-threatening malignancy/disease within the last 5 years, except very low-risk prostate cancer
Diagnosis of another malignancy within 2 years before the first dose of study treatment, except for superficial skin cancers, or localized, low grade tumors deemed cured and not treated with systemic therapy; malignancy felt by investigator to potentially affect subject survival or ability to evaluate disease response
Has a known additional malignancy that is progressing or requires active treatment
Concurrent malignancy requiring cytotoxic or immunotherapy based treatment
Patients must not have received treatment for another malignancy within 3 years of enrollment
Evidence of active malignancy other than CD19+ malignancy
Any history of or current hematologic malignancy
Prior malignancy or therapy for a malignancy within 3 years
No other active malignancy
Subject has any other active malignancy besides the tumor under study within 3 years prior to Screening. Subject has uncontrolled intercurrent illness.
Participants with presence of other active malignancy within 2 years of study entry; participants with history of prior malignancy treated with curative intent and achieved CR within 2 years are eligible.
Concurrent active malignancy that requires systemic treatment
Other active malignancy receiving systemic therapy.
Other active malignancy requiring concurrent intervention; a history of prior malignancy will not be an exclusion factor as long as the patient is not currently requiring treatment for this malignancy
Second invasive malignancy requiring active treatment
Active malignancy
No active or co-existing malignancy requiring chemotherapy or radiation within 6 months
Have a known additional malignancy that is progressing or required active treatment within the past 1 year.
Has positive urine cytology for urothelial malignancy at screening.
The presence of any other concurrent active malignancy
Patients with concurrent second malignancy. Persons with previous malignancies effectively treated and not requiring treatment for >24 months are eligible, provided there is unambiguous documentation that current local recurrence or metastatic site represents recurrence of the primary breast malignancy.
MALIGNANCY CRITERIA:
Metastatic disease or currently active second malignancy
Active CNS malignancy
Diagnosed with another concurrent malignancy requiring treatment
No previous cancer treatment with any cytotoxic agent for this malignancy
History of other malignancy that could affect compliance with the protocol or interpretation of results
Have active malignancy with the exception of nonmelanoma skin cancer, as determined by the investigator. Subjects who experience relapse or progression of their underlying malignancy (for which HSCT was performed), as determined by the investigator, are not to be enrolled.
Second primary malignancy
Other malignancy within 2 years prior to screening, with some exceptions
Patients with a currently active second malignancy excluding non-melanomatous skin cancer or superficial transitional cell carcinoma\r\n* Note: Patients are not considered to have a \currently active\ malignancy if they have completed all therapy and are now considered without evidence of disease for 1 year
Active cerebral/meningeal disease related to the underlying malignancy
Histologic/molecular diagnosis of malignancy at diagnosis or the time of relapse
Active malignancy besides NSCLC within 3 years prior to screening.
Concurrent malignancy or malignancy within 3 years prior to starting study drug, except\r\n* Malignancies that have completed therapy and are considered by their physician to be at less than 30% risk of relapse, or\r\n* Malignancies not requiring treatment (e.g., RAI stage 0 chronic lymphocytic leukemia [CLL])
No prior history of malignancy within 2 years, unless cured of a skin cancer or a stage I-III solid tumor; no prior hematologic malignancy within 3 years
Subjects with a history of prior malignancy with the exception of carcinoma in situ of the cervix or other malignancy diagnosed > 2 years ago that has undergone potentially curative therapy with no evidence of disease for the last >= 2 years and that is deemed by the investigator to be at a low risk of recurrence
Are currently receiving other medications or radiation intended for the treatment of their malignancy
History of malignancy other than their lymphoma with the exception of:
Has a known additional malignancy that is progressing or requires active treatment; patients with a stage I-III cancer that has been cured over two years ago are not excluded in the study
Previous therapy for any malignancy with an anthracycline or taxane for Cohorts A and B and carboplatin for Cohort A
Has known active additional malignancy that is undergoing active treatment
A second primary malignancy that in the judgment of the principal investigator (PI) or designee may affect the interpretation of results
Presence of an active hematological malignancy:
Active second malignancy or other prior malignancy treated with chemotherapy less than or equal to 6 months prior to treatment with CK-101
No evidence of an active malignancy that would limit the patient’s survival to less than 2 years. (If there is any question, the principal investigator [PI] can make a decision)
Presence of relapsed primary malignancy, or who have been treated for relapse after the alloHSCT was performed, or who may require rapid immune suppression withdrawal as pre-emergent treatment of early malignancy relapse.
Immunosuppression, not related to prior treatment for malignancy.
No other active second malignancy other than non-melanoma skin cancers and in situ cervical cancers within 5 years of registration\r\n* NOTE: A second malignancy is not considered active if all treatment for that malignancy is completed and the patient has been disease-free for at least 5 years prior to registration
Patients must not have current evidence of another malignancy that requires treatment
Patients with another active second malignancy other than non-melanoma skin cancers and biochemical relapsed prostate cancer; patients that have completed all necessary therapy and are considered to be at less than 30% risk of relapse are not considered to have an active second malignancy and are eligible for enrollment
Histologic confirmation of malignancy
Does not have any other active malignancy other than the one for which this transplant is indicated
Pathologically proven diagnosis of a non-hematopoietic malignancy other than small cell lung cancer and germ cell malignancy within 5 years of registration; patients with metastasis of unknown primary tumor are permitted
Previous malignancy is not an exclusion provided that the other malignancy is considered under control, patient is not on concomitant anti-cancer drug therapy, and target lesions from melanoma are clearly defined for response assessment
Patients with history of hematologic malignancy
Has a history of another malignancy.
Active treatment of a separate malignancy
Diagnosis of breast malignancy
Patients with prior malignancy and treated with no evidence of active disease, and more than 2 years from initial diagnosis are eligible
Recurrent or progressive malignancy requiring anticancer treatment
Second active malignancy requiring systemic therapy
Patients must have a confirmed recurrent/progressive brain malignancy that have failed at least one prior treatment regimen
Presence of a concurrent active, incurable malignancy that may alter the outcome of the treatment for esophageal cancer as determined by the treating physician
Has a known additional malignancy that is progressing or requires active treatment
CAPMATINIB EXCLUSION CRITERIA: Diagnosis of concurrent malignancy or previous malignancy within 3 years before study drug administration (exceptions are superficial skin cancers, or any in situ cancers deemed surgically resected, cured and not requiring systemic therapy, and indolent malignancies that currently do not require treatment)
CERITINIB EXCLUSION CRITERIA: Diagnosis of concurrent malignancy or previous malignancy within 3 years before study administration (exceptions are superficial skin cancers, or any in situ cancers deemed surgically resected, cured and not requiring systemic therapy)
REGORAFENIB EXCLUSION CRITERIA: Diagnosis of concurrent malignancy or previous malignancy within 3 years before study drug administration (exceptions are superficial skin cancers, or any in situ cancers deemed curatively treated and without evidence of disease for more than 3 years before regorafenib treatment)
Patients with evidence of another malignancy, exclusive of a skin cancer that requires only local treatment, should not be enrolled on this protocol
History of other malignancy within the last 3 years (with exceptions).
Participants with a history of other malignancy within 5 years prior to screening
Patient has a concurrent active malignancy under treatment
Patients with malignancy that is suspected or proven to have progressed, relapsed, or be persistent since progressive, relapsed or persistent malignancy documented since BMT
Patients with prior malignancy successfully treated who are currently stable and on no active treatment are eligible
Has a known additional malignancy that is progressing or requires active treatment
Has a malignancy:
Evidence of other active invasive malignancy requiring treatment other than surgery in the past 3 years
Individuals with a history of a different malignancy (other than acute leukemia) are ineligible except for the following circumstances:\r\n* Individuals are eligible if the different malignancy is in complete remission at time of study entry
Patients with a hematologic malignancy or solid tumor
Patients with more than one malignancy (hematologic or solid tumor) are eligible
Any history of or current hematologic malignancy
Previous malignancy within 2 years of the first dose of study drugs, except tumors totally resected and/or not requiring therapy
A history of other malignancy =< 5 years previous which would preclude endocrine treatment of their cancer
Patients with active secondary malignancy unless approved by the study chair
Subject has a known additional malignancy that is progressing or requires active treatment
No active prior malignancy within 3 years of registration (with the exception of non-melanoma skin cancer, in-situ cancers, or Rai stage 0 chronic lymphocytic leukemia [CLL]); if patient is disease free from a prior malignancy between 3-5 years, special consideration can be requested; in these cases, if the risk of recurrence at 5 years is less than 20%, and in the opinion of the investigator the prior malignancy will not affect the patient's outcome in light of newly diagnosed pancreatic cancer, the patient may be eligible; this will require principal investigator (PI) review and approval on a case by case basis, and approval will be documented in the medical record; all patients who have been disease free from a prior malignancy for at least 5 years will be eligible
Progressive hemato-lymphoid malignancy despite conventional therapy
Prior malignancy (EXCEPTION: diagnosed > 5 years ago without evidence of disease, OR treated =< 5 years ago but have a greater than 50% chance of life expectancy of >= 5 years for that malignancy)
History of another primary invasive malignancy that has not been definitively treated or in remission for at least 2 years; patients with non-melanoma skin cancers or with carcinomas in situ are eligible regardless of the time from diagnosis (including concomitant diagnoses); if patients have another malignancy that was treated within the last 2 years, such patients may be enrolled if the likelihood of requiring systemic therapy for this other malignancy within 2 years is less than 10%, as determined by an expert in that particular malignancy at MD Anderson Cancer Center and after consultation with the principal investigator
Prior malignancy in past 2 years or as identified in Section 7.2 of this protocol
No other active malignancy
No active malignancy at the time of enrollment, except nonmelanoma skin cancers or carcinoma in situ; patients with a prior history of malignancy are eligible if their malignancy has been definitely treated or is in remission and does not require ongoing adjuvant or cancer-directed therapies
Other active malignancy requiring concurrent intervention
Previous chemotherapy for any malignancy, if given within three years of registration
Research participants with presence of other active malignancy; however, research participants with history of prior malignancy treated with curative intent and in complete remission are eligible; any history of myelodysplasia is excluded
Relapsed malignancy after transplantation
Second primary malignancy only if treatment would interfere with the patient’s participation in this trial in the opinion of the treating physician; clear exceptions are 1) patient had a second primary malignancy but has been treated and disease free for at least 3 years, 2) in situ carcinoma (e.g. in situ carcinoma of the cervix) and, 3) additional skin cancers that have been definitively treated by surgery and/or radiation; patients with chronic lymphocytic leukemia will be allowed if their blood counts are within acceptable hematologic parameters and if they are not currently requiring cytotoxic or biologic anticancer treatment (supportive treatment such as intravenous immunoglobulin [IVIG] is permitted)
Patients who have a history of another primary malignancy unless the patient has been disease free for >= 3 years
Patient does NOT have an active malignancy other than NB
Active and uncontrolled relapse of malignancy.
Other active malignancy requiring treatment that would interfere with the assessments of response of the lymphoma to protocol treatment
No currently active second malignancy
Active and uncontrolled relapse of malignancy
Active and uncontrolled relapse of malignancy
Any other active malignancy
Having \currently active\ second malignancy unrelated to HL or NHL, unless they have completed anti-cancer therapy, are in complete response and are considered by their physicians to be at less than 30% risk of relapse
Be aware of the nature of her malignancy
Research participants with presence of other active malignancy; However, research participants with history of prior malignancy treated with curative intent and in complete remission are eligible
Research participants with presence of other active malignancy; however, research participants with history of prior malignancy treated within 2 years with curative intent and in a complete remission are eligible
Research participants with presence of other active malignancy; however, research participants with history of prior malignancy treated with curative intent and in complete remission are eligible
Concurrent active malignancy of another type
Patients with active secondary malignancy will not be eligible unless approved by the principal investigator
Treatment for non-hematologic malignancy greater than 6 months prior to enrollment is acceptable
Active and uncontrolled relapse of malignancy
Other malignancy within five years, except the following may be eligible:
There is no evidence of the second malignancy at the time of study entry
Histological or cytological evidence of solid malignancy.
Uncontrolled, non-hematologic malignancy requiring active treatment
Histologically or genetically proven unilateral primary or metastatic active pleural malignancy
Other active malignancy (other than malignancies, which the investigator determines are unlikely to interfere with treatment and safety analysis)
Hematologic or lymphoid malignancy
Prior history of invasive malignancy within the last 2 years
Patients with a current second malignancy requiring systemic therapy, other than non-melanoma skin cancers, are not eligible; if a patient has had a prior second malignancy that is not currently requiring active treatment, the patient will be considered eligible
RECIPIENT: Presence of active malignancy in another organ system other than the hematopoietic, except when driven by viruses in which case the immune reconstitution after transplant may control the malignancy
Presence of malignancy.
Does not have any other active malignancy other than the one for which this HCT is indicated
Neoadjuvant chemotherapy for current malignancy
Patients with evidence of another malignancy, exclusive of a skin cancer that requires only local treatment, should not be enrolled on this protocol
Patients receiving active treatment or intervention for any other malignancy or patients who, at the investigator’s discretion, may require active treatment or intervention for any other malignancy within 8 months of starting study treatment
Other malignancy that would interfere with the current intervention
No malignancy (other than the one treated in this study) which required radiotherapy or systemic treatment within the past 5 years
Patients with a history of any other malignancy, except patients with a secondary brain tumor if the patient’s first malignancy has been in remission for at least 5 years from the end of treatment
Known additional malignancy that is progressing or requires active treatment.
Confirmed diagnosis of select advanced malignancy
Concurrent active invasive malignancy or one previously diagnosed with a greater than 30% chance of recurrence in the next two years
EXCLUSION CRITERIA FOR REGISTRATION: concurrent active invasive malignancy or one previously diagnosed with a greater than 30% chance of recurrence in the next two years
Patients with evidence of another malignancy, exclusive of a skin cancer that requires only local treatment, should not be enrolled on this protocol
Non-hematopoietic malignancy where the expected survival is less than 2 years
No active extramedullary leukemia or known active CNS involvement by malignancy; such disease treated into remission is permitted
Presence of active malignancy in another organ system other than the hematopoietic system, except when driven by viruses in which case the immune reconstitution after transplant may control the malignancy
Patients with concurrent malignancy except for nonmelanoma skin lesions
No chemotherapy for a malignancy in the last 5 years
Concurrent malignancy or history of other malignancy within the last five years except as noted above
Patients with a prior malignancy treated < 5 years ago but have a life expectancy of > 5 years for that malignancy are eligible
No active secondary malignancy; patients with other prior malignancies will be included, provided they have been disease-free for at least five years
Patients with therapy-related AML whose prior malignancy has been in remission for at least 12 months
Active second malignancy
Resistant malignancy
Active second malignancy
Subject has another malignancy for which treatment is required.
Cold agglutinin syndrome secondary to infection, rheumatologic disease, or active hematologic malignancy
Relapsed or progressive malignancy after transplant, post-transplant lymphoproliferative disease or any secondary malignancy diagnosed after HCT
A concurrent second active and nonstable malignancy
History of documented adrenal dysfunction not due to malignancy.
Has a known additional malignancy that is progressing or requires active treatment.
History of documented adrenal dysfunction not due to malignancy.
Other active, concurrent malignancy that requires ongoing systemic treatment or interferes with radiographic assessment of melanoma response as determined by the investigator.
History of a non-lymphoid malignancy except for protocol allowed exceptions
Any malignancy
Patients with any other prior malignancy are not allowed except for the following:
History of malignancy;
History of another primary malignancy
Has another active systemic malignancy treated with chemotherapy within 12 months before baseline (C1D1).
Patients with a history of a second malignancy within 3 years of the baseline visit excluding cutaneous carcinomas and in-situ carcinoma.
Patients with a second malignancy requiring active treatment
Malignancies other than disease under study are excluded, except for any other malignancy from which the subject has been disease-free for more than 2 years and, in the opinion of the principal investigators and GSK Medical Monitor, will not affect the evaluation of the effects of this clinical trial treatment on the currently targeted malignancy (MM).
History of another primary malignancy that has not been in remission for at least 2 years.
An active second malignancy or history of another malignancy within the last 5 years, with exceptions.
Concurrent malignancy requiring active therapy
Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
Presence of a concurrent active, incurable malignancy that may alter the outcome of the treatment for disease under treatment as determined by the treating physician
Malignancy within the last 3 years
History of any malignancy within the last 6 months except for those specified in this protocol and low-grade malignancies not requiring active treatment.
Prior malignancy in past 2 years or as identified in Section 7.2 of this protocol
Patients must not have a concurrent active malignancy for which they are receiving treatment
Known active malignancy as determined by treating medical and radiation oncologist.
Has a known additional malignancy that is progressing or requires active treatment
Active concomitant second malignancy (i.e. has required treatment in the previous 6 months)
History of concurrent malignancy requiring active therapy or prior history of another malignancy within 5 years.
Chemotherapy-naive patients (for this malignancy)
Patients receiving any other standard or investigational treatment for their hematologic malignancy
Patients with a history of another malignancy within 5 years of study enrollment
Subjects with active other malignancy diagnosed in the past 3 years (excepting in situ tumors)
Uncontrolled prior invasive malignancy, excluding the current diagnosis
Individuals with a history of a previous malignancy are ineligible; exception: individuals with a previous malignancy treated with surgery only (no chemotherapy or radiotherapy) more than 5 years prior to registration may be enrolled
Known past or current malignancy other than inclusion diagnosis, except for:
Second primary malignancy, only if it would affect the safety of the treatment or the subject’s ability to complete study-related procedures
Second malignancy within the last 3 years
Known additional malignancy that is progressing or requires active treatment or that may interfere with interpretation of response evaluation, in the judgment of the investigator
Have active malignancy with the exception of nonmelanoma skin cancer. Subjects who have had a hematopoietic stem cell transplant (HSCT) and who experience relapse or progression of the malignancy as per investigator's opinion are not to be enrolled.
Second primary invasive malignancy that has not been in remission for greater than 2 years.
Bilateral breast malignancy
Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured
History of other malignancy within 2 years prior to screening
Patient must not have a concurrent active malignancy for which they are receiving treatment (other than myelodysplastic syndromes [MDS])
History of prior invasive rectal malignancy, regardless of disease-free interval
Other active malignancy requiring concurrent intervention
Prior chemotherapy for any malignancy
Concurrent second malignancy or history of HER2 negative breast cancer within five years
Presence of malignancy other than the study indication under this trial within 3 years of study enrollment
History of prior malignancy
Active other malignancy requiring treatment that would interfere with the assessments of response of the lymphoma to protocol treatment
Individuals with a history of a previous malignancy are ineligible; also, exposure to previous anti-neoplastic treatment may alter the ability to tolerate or respond to the agents utilized in this protocol; exception: individuals with a previous malignancy treated with surgery only (no chemotherapy or radiotherapy) more than 5 years prior to registration may be enrolled
History of prior malignancy, with the exception of the following:
Active second malignancy i.e. patient known to have potentially fatal cancer present\n             for which he/she may be (but not necessarily) currently receiving treatment
Patients who have a history of any hematopoietic malignancy
Active second malignancy other than non-melanoma skin cancer or cervical carcinoma in situ; (patients with history of malignancy are not considered to have a “currently active” malignancy if they have completed therapy and are now considered by their physician to be at less than 30% risk for relapse)
Other malignancies unless the patient is considered to be disease-free and has completed therapy for the malignancy > than 6 months prior to study entry
Patient has a concurrent advantage active malignancy under treatment
Other malignancy requiring active treatment
Concurrent diagnosis of another malignancy if either systemic treatment or surgery is expected to be required within 2 years from study entry
Patient has another active malignancy
Any active secondary malignancy
Second malignancy requiring active therapy
Concurrent other malignancy with the exception of: \r\n* Cutaneous squamous cell and basal carcinomas\r\n* Adequately treated stage 1-2 malignancy\r\n* Adequately treated stage 3-4 malignancy that has been in remission for >= 2 years at the time of registration
Active second malignancy other than non-melanoma skin cancer or cervical carcinoma in situ; (patients with history of malignancy are not considered to have a \currently active\ malignancy if they have completed therapy and are now considered by their physician to be at less than 30% risk for relapse)
Concurrent malignancy other than the solid tumor under investigation, requiring\n             active treatment.
Evidence of active second malignancy
Patients must have had histologic verification of the malignancy at original diagnosis or at the time of recurrence
Subjects who have an uncontrolled systemic malignancy that is not in remission
Patients must have had histologic verification of malignancy at original diagnosis or relapse
Untreated or uncontrolled 2nd malignancy
Patients who have an active 2nd malignancy requiring systemic treatment
Is being actively treated for another concurrent malignancy or is less than five years from completion of treatment for another malignancy
Cerebral/meningeal disease related to the underlying malignancy that has not been definitively treated
History of another malignancy, unless the candidate has been disease-free for at least 5 years.
Patient is < 5 years free of another primary malignancy, except: a) if the other malignancy is basal cell carcinoma or cervical carcinoma in situ or b) if the other primary malignancy is not considered clinically significant and is requiring no active intervention
Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured
The participant has a concurrent active malignancy other than the following:
Prior malignancy active within the previous 3 years except for locally curable cancers
Subjects with second malignancies in addition to myeloma if the second malignancy has required therapy in the last 3 years or is not in complete remission
Subjects with a history of another invasive malignancy ?3 years of study drug initiation.
No other current active malignancy requiring anticancer therapy.
Part 3: advanced solid tumor or hematologic malignancy
History of prior malignancy except:
Prior malignancy except for any of the following:
Known additional malignancy that is progressing or has required active treatment within the past 3 years.
Has a known additional malignancy that is progressing or requires active treatment within the past 5 years.
Relapsed, progressing or persistent malignancy requiring withdrawal of systemic immune suppression.
Known additional malignancy that required treatment or progressed in last 5 years
History of other malignancy within the last 5 years
Patients may not have a \currently active\ second malignancy other than non-melanoma skin cancers; patients are not considered to have a \currently active\ malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse
Diagnosis of another malignancy within 2 years before randomization, except for superficial skin cancers, or localized, low-grade tumors.
Prior treatment for lymphoid malignancy:
Other invasive malignancy within the past 3 years.
Active cerebral/meningeal disease related to the underlying malignancy.
History of another invasive malignancy that has not been in remission for at least 3 years
Previous or concurrent malignancy with the following exceptions:
A primary malignancy which has been completely resected and in complete remission for ? 5 years
Have a concurrent malignancy or had another malignancy within 5 years (?5 years) of study enrollment.
History of tuberous sclerosis, lymphangioleiomyomatosis (LAM) or any active malignancy
Non-squamous malignancy of the penis
Known history of another primary malignancy that has not been in remission for ?2 years
Evidence within the last 2 years of another malignancy which required systemic treatment
Patients with another uncontrolled malignancy; patients with a previous malignancy, treated curatively and without evidence of disease relapse are eligible
History of malignancy other than pancreatic carcinoma within 2 years prior to screening, with the exception of those with a negligible risk of metastasis or death
History of malignancy other than NSLCL within 5 years prior to screening with the exception of malignancies with negligible risk of metastasis or death
History of any other malignancy other than skin cancer, or low grade bladder cancer which has been completely resected, within the previous 2 years. Patients that have had curative treatment of a previous malignancy and no recurrence of that malignancy within the past 2 years will be allowed.
Subject has another active malignancy requiring concurrent intervention;
one or more of the following biomarkers of malignancy:
Have prior malignancy active within the previous 2 years;
History of other malignancy with the past 2 years with some exceptions
No other active second malignancy other than non-melanoma skin cancers within 3 years of pre-registration; a second malignancy is not considered active if all treatment for that malignancy is completed and the patient has been disease-free for at least 3 years prior to pre-registration
Prior malignancy in the last 5 years, unless curatively treated and recurrence free (few exceptions apply).
Prior malignancy.
Subject has a history of a malignancy (other than the disease under treatment in the study) within 5 years before first study treatment administration
History of other malignancy that could affect compliance with the protocol or interpretation of results
Any active malignancy (other than BRAF-mutated melanoma) or a previous malignancy within the past 3 years
History of a prior invasive malignancy in past 5 years
Patients with prior malignancy (other than AML and MDS/CMML) are eligible; however, the patient must be in remission from the prior malignancy and have completed all chemotherapy and radiotherapy at least 6 months prior to registration; except for AML and MDS treatment, all treatment related toxicities must have been resolved; NOTE: for patients with prior history of malignancy who have received anthracyclines or mediastinal/pericardial radiation in the past, the risk versus benefit of therapy should be weighed, particularly in the setting of receiving consolidation therapy
Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured
History of other malignancy within the past 3 years with the following exceptions:
History of another primary invasive cancer, hematologic malignancy, or myelodysplastic syndrome that has not been in remission for at least 3 years
Cerebral/meningeal disease related to the underlying malignancy
Concurrent active malignancy other than non-melanoma skin cancers; patients are considered to be free of active malignancy if they have completed curative therapy and have a < 30% risk of relapse
History of other malignancy that could affect compliance with the protocol or interpretation of results
Currently active second primary malignancy.
There is any evidence of other malignancy being present within the last three years;
Other active malignancy
Known additional malignancy that is progressing or has required active treatment within the past 3 years.
Known additional malignancy that is progressing or has required active treatment within the past 3 years.
Known additional malignancy that has progressed or has required active treatment in the last 3 years.
Active secondary malignancy
Patient has a history of hematological malignancy within the last 5 years prior to study entry
History of a concurrent or second malignancy except for those outlined in protocol
Have a previous malignancy within 5 years of study entry or a concurrent malignancy.
Prior invasive malignancy unless disease-free for a minimum of 5 years
History of another malignancy within 3 years
Patient is < 5 years free of another primary malignancy, except: a) if the other malignancy is basal cell carcinoma or cervical carcinoma in situ or b) if the other primary malignancy is not considered clinically significant and is requiring no active intervention
History of other malignancy that could affect compliance with the protocol or interpretation of results
Patients must not have another active second malignancy other than non-melanoma skin cancers and biochemical relapsed prostate cancer; patients that have completed all necessary therapy and are considered to be at less than 30% risk of relapse are not considered to have an active second malignancy and are eligible for enrollment
Known other active malignancy (other than malignancies which the investigator determines are unlikely to interfere with treatment and safety analysis)
other effectively treated malignancy that has been in remission for more than 5 years and is considered to be cured
Any other malignancy requiring treatment
Participants with a previous malignancy within the past 3 years
History of other malignancy that could affect compliance with the protocol or interpretation of results
Known past or current malignancy other than inclusion diagnosis, except for:
Any active malignancy within 3 years that may alter the course of esophageal cancer; (apparently cured localized malignancy or advanced, but indolent malignancy with significantly more favorable prognosis are allowed)
Prior invasive non-breast malignancy unless disease free for a minimum of 1 year prior to registration
Invasive malignancy other than melanoma at the time of enrollment or within 5 years prior to first dose of study treatment
Subjects with history of other malignancy within past 5 years (with exceptions)
No active co-existing malignancy with life expectancy less than 12 months due to that malignancy
Patient is < 3 years free of another primary malignancy except: if the other primary malignancy is not currently clinically neither significant nor requiring active intervention, or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ; existence of any other malignant disease is not allowed
Other active, concurrent malignancy that requires ongoing systemic treatment or interferes with radiographic assessment of melanoma response as determined by the investigator
Other malignancy within the last 5 years
Any other current or previous malignancy within 3 years except protocol allowed malignancies
Prior or current malignancy that does not require concurrent treatment;
Subject has been diagnosed with another malignancy that requires concurrent treatment or hepatic malignancy regardless of need for treatment.
Advanced measurable malignancy
Patients with another primary malignancy that has not been in remission for at least 3 years.
Second malignancy: No \currently active\ second malignancy other than non-melanoma skin cancers.
Known additional malignancy that is progressing or requires active treatment
Active malignancy of metastatic potential other than the known carcinoid or pancreatic NET within the past three years
Other malignancy within 5 years except for noninvasive malignancies
Patient has positive urine cytology for malignancy at Screening.
Currently active second primary malignancy or history of malignancy less than 5 years prior to the time of study eligibility (patients with history of skin cancers excluding melanoma will be eligible for participation)
History of any other malignancy
Patient has a concurrent active malignancy under treatment
Patients who have been continuously disease-free for any solid tumor malignancy >3 years prior to the time of enrollment.
History of another primary malignancy
Known additional malignancy that is progressing or requires active treatment
Other malignancy within 2 years prior to Day 1 of the study, except for those treated with surgical intervention only.
Other active malignancy requiring concurrent intervention
Patients with a history of any other malignancy will not be eligible
Concurrent second malignancy or past malignancy with > 30% estimated risk of relapse in next 5 years; EXCEPTIONS: non-melanotic skin cancer or carcinoma-in-situ of the cervix; NOTE: if there is a history or prior malignancy, patient must not be receiving active treatment for this malignancy cancer
Second malignancy within the past 5 years except:
Diagnosis of another malignancy within 2 years of enrollment, except for superficial skin cancers, or localized, low grade tumors deemed cured and not treated with systemic therapy by the principal investigator
Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured
History of hematologic or primary solid tumor malignancy, unless no evidence of that disease for 5 years
Patients with a history within the last 3 years of another invasive malignancy.
Concurrent malignancy requiring active therapy \r\n* Patients with more than one type of lymphoma may be enrolled after discussion with the MSK principal investigator
History of other malignancy, which could affect compliance with the protocol or interpretation of results
another primary malignancy
Patient has an active concurrent malignancy requiring active therapy
Any concurrent and/or other active malignancy that has required treatment within 2 years of first dose of study drug.
History of prior malignancy for which patient is receiving other specific treatment for their cancer
Patients must not have other active concurrent malignancy
Other invasive malignancy within 2 years
Any prior history of hematologic malignancy (other than CTCL) within past 5 years
Another primary malignancy
Concurrent other malignancy with the exception of: a) cutaneous squamous cell and basal carcinomas, b) adequately treated stage 1-2 malignancy, c) adequately treated stage 3-4 malignancy that had been in remission for >= 2 years at the time of registration
History of other malignancy (not including the underlying malignancy that was the indication for transplant)
History of other primary malignancy (including myeloid malignancy, e.g., myelodysplastic syndrome), unless
Other malignancy curatively treated with no known active disease present and no systemic treatment administered for 3 years before the first dose of study drug
Patients with a previous malignancy (other than the patients' known cancer) that were treated successfully and are disease-free for at least 3 years are allowed
Presence of malignancy (other than the one treated in this study) which required systemic treatment within the past 3 years
Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention, other than non-melanoma skin cancer and carcinoma in situ of the cervix should not be enrolled; patients are not considered to have a “currently active” malignancy if they have completed therapy for a prior malignancy, are disease free from a prior malignancy for >= 5 yrs and are considered by their physician to be less than 30% risk of relapse
History of documented adrenal dysfunction not due to malignancy.
Patients with a \currently active\ second malignancy other than non-melanoma skin cancers are not eligible; patients are not considered to have a \currently active\ malignancy if they have completed all therapy and are now considered without evidence of disease for 1 year
Research participants with presence of other active malignancy; however, research participants with history of prior malignancy treated with curative intent in complete remission are eligible
Patients with a \currently active\ second malignancy other than non-melanoma skin cancers are not to be registered; patients are not considered to have a \currently active\ malignancy if they have completed therapy and considered by their physician to be at less than 30% risk of relapse
Prior history of metastatic malignancy
Individuals with a history of other malignancies are eligible if they have been disease free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy
Other malignancy within five years, except that the following may be eligible:
Actively being treated for other malignancy; if there is a history of prior malignancy, patient must not be receiving other specific treatment for their cancer
History of another active uncontrolled malignancy at the time of study enrollment
Previous therapy with any HER2 TKI (such as trastuzumab, lapatinib, neratinib, etc.) for any malignancy.
Patients must not have an active secondary malignancy
Currently active second malignancy
History of another malignancy. Subjects with another malignancy are eligible if: (a) disease-free for 3 years, or (b) have a history of completely resected non-melanoma skin cancer, and/or (c) have an indolent second malignancy(ies).
Diagnosis of malignancy must be confirmed by the department of pathology at the institution where the patient is being enrolled prior to patient enrollment
No other active malignancy
Active morphologic relapse/progression of hematologic malignancy post transplantation.
Has history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years
Patients with a currently active second malignancy requiring treatment
Active concurrent malignancy requiring active therapy
Individuals with a history of a different malignancy and are on treatment for the malignancy or the malignancy is documented on screening or other imaging are ineligible; individuals with a history of other malignancies are eligible if they are deemed by the investigator to be at low risk for recurrence of that malignancy
Presence of malignancy other than the study indication under this trial within 5 years of study enrollment
Patients with a concurrent malignancy
Patients may not have a \currently active\ second malignancy other that non-melanoma skin cancers; patients are not considered to have a \currently active\ malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse
Participants must not have a concurrent malignancy unless it can be adequately treated by non-chemotherapeutic intervention; participants may have a history of prior malignancy, provided that he/she has not had any chemotherapy within 365 days of study entry AND that life expectancy exceeds 5 years at the time of study entry
Concurrent or prior malignancy except for the following:
Patients with more than one active malignancy at the time of enrollment.
History of another primary invasive malignancy that has not been in remission for at least 3 years
Cerebral/meningeal disease related to the underlying malignancy
History of metastatic malignancy in the preceding 2 years
Concurrent other malignancy
Patients who have had a previous malignancy that is not in remission
Active concurrent malignancy requiring active therapy
Subjects with another active malignancy
Other invasive malignancy within 2 years
Stable primary malignancy for previous 3 months
Active treatment/chemotherapy for another primary malignancy within the past 5 years
A concurrent second malignancy even if it does not require active therapy; patients with indolent B-cell malignancies will not be eligible; prior malignancy will be allowed as long as the patient is known to be free of disease for at least 3 years
Relapse of primary hematologic malignancy that served as indication for HCT
Prior malignancy active within past 3 years, except for locally curable cancers
Have borderline malignancy
No currently active second malignancy
No malignancy (other than for which patient underwent transplant) which required radiotherapy or systemic treatment within the past 5 years
Biopsy confirmed malignancy of the gynecologic tract
A second malignancy requiring active therapy
Second primary malignancy that may affect the interpretation of results
Participants with history of another primary malignancy not in remission for at least 3 years
Patients with a \currently active\ second malignancy other than non-melanoma skin cancers are not eligible; patients are not considered to have a \currently active\ malignancy if they have completed all therapy and are now considered without evidence of disease for 1 year
The patient has a recently diagnosed active malignancy requiring therapy
Individuals with a history of a different active malignancy are ineligible
Active second malignancy, i.e., patient known to have potentially fatal cancer present for which she may be (but not necessarily) currently receiving treatment a. Patients with a history of malignancy that has been completely treated, with no evidence of that cancer currently, are permitted to enroll in the trial provided all chemotherapy was completed >6 months prior and/or bone marrow transplant (BMT) >2 years prior to first dose of rucaparib
Patients with a prior malignancy will NOT be eligible for participation aside from the following exception:\r\n* Patients who have had any curatively treated malignancy and have been disease free without treatment for 1 year prior to study entry ARE eligible for participation
No currently active other (second) malignancy, other than non-melanoma skin cancers; patients are not considered to have a “currently active” malignancy if they have completed anti-cancer therapy and are considered by their physicians to be at less than 30% risk of relapse
Patients must have pathologically-confirmed malignancy
Subjects with no additional active malignancy within the last 3 years
Time since last therapy for treatment of underlying malignancy:
Concurrent active malignancy requiring immediate therapy
Prior therapy for advanced malignancy with no current curative option
Patients with prior malignancies diagnosed > 5 years ago without evidence of disease are eligible; patients with a prior malignancy treated < 5 years ago but have a life expectancy of > 5 years for that malignancy are eligible
No active or co-existing malignancy (other than ALL or lymphoblastic lymphoma) with life expectancy less than 12 months due to that malignancy
Presence of active malignancy from an organ system other than hematopoietic
E 08. Prior malignancy.
Known history of or concomitant malignancy likely to affect life expectancy in the judgment of the investigator
History of metastatic malignancy in the preceding 2 years
Active other malignancy requiring treatment that would interfere with the assessments of response of the lymphoma to protocol treatment
Patients who have had a previous malignancy that is not in remission
No “currently active” second malignancy other than non-melanoma skin cancers; patients are not considered to have a “currently active” malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse
Diagnosis of another malignancy within 2 years before first dose of study treatment.
History of prior malignancy within 3 years; patients who are considered no evidence of disease (NED) from a malignancy may be considered on a case by case basis
Other malignancy within the last 5 years (few exceptions apply);
An active malignancy that requires concurrent intervention
Concomitant malignancy;
Receiving any treatment for persistent, progressive or recurrent malignancy.
Progressive or recurrent malignancy defined other than by quantitative molecular assays.
Patients with active second malignancy are allowed as long as it is determined that the treatment of esophageal cancer is a higher priority through proper subspecialty consultations
History of another primary malignancy that has not been in remission for at least 3 years
Prior malignancy (excluding nonmelanoma carcinomas of the skin) unless in remission for 2 years.
History of other malignancy that could affect compliance with the protocol or interpretation of results
Individuals with a history of a different malignancy are ineligible except for the following circumstances: individuals with a history of other malignancies are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy
Invasive or active malignancy in past 2 years
Recurrence or progression of primary malignancy after HCT
Diagnosis of malignancy must be confirmed by the department of pathology at the institution where the patient is enrolled prior to patient enrollment
Patients must have indications for treatment for their B cell malignancy at the time of enrollment on this trial
Other active malignancy
Patients with a prior malignancy allowed if > 5 years ago with no current evidence of disease
Diagnosis of hematologic malignancy and at least one of the criteria as specified above
Active or recent second malignancies unless they have undergone potentially curative therapy for that malignancy and (1) have had no evidence of that disease for 5 years, and/or (2) be deemed at low risk for recurrence (less than or equal to 20% at 5 years)
Patients with prior malignancies diagnosed > 5 years ago without evidence of disease are eligible; patients with a prior malignancy treated < 5 years ago but have a life expectancy of > 5 years for that malignancy are eligible
Patients with an active, or likely to become active second malignancy.
No invasive tumors within the last 5 years unless confined to an organ (e.g. prostate or thyroid cancer) and treated with curative therapy (e.g. surgery and/or radiation); please note, there must be no evidence of the prior malignancy using standard criteria to evaluate the specific prior malignancy
Active malignancy with the exception of any of the following:
Cerebral/meningeal disease related to underlying malignancy
History of other active malignancy within the prior 2 years
Subjects with relapsed/persistent malignancy requiring rapid immune suppression withdrawal.
Has a history of a malignancy, unless potentially curative treatment has been completed, with no evidence of malignancy for 5 years
Concurrent active malignancy requiring immediate therapy
Patients with a history of other invasive malignancies are excluded if there is any evidence of other malignancy being present within the last 3 years
Concurrent active malignancy other than AML requiring therapy
Patients who have had a previous malignancy unless they are deemed by their treating physicians to be at low risk for recurrence
Active second malignancy; i.e., patient known to have potentially fatal cancer present for which he/she may be (but not necessarily) currently receiving treatment
Concurrent malignancy other than SCLC. History of other malignancy is allowed as long as there is no evidence of active disease or need for treatment.
Subjects being actively treated for a secondary malignancy.
Patients with active concurrent malignancy, other than superficial, non-invasive squamous cell carcinoma of the skin or uterine cervix, within the past three years; an active concurrent malignancy will be defined as one currently requiring cancer-directed treatment, or deemed by the treating physician as likely to require such treatment within a six-month period from time of screening
Active treatment for a secondary malignancy
Patients with a concurrent active malignancy (with the exception of skin cancer)
Any history of another metastatic malignancy
Secondary malignancy, with the exception of:
History of documented adrenal dysfunction not due to malignancy.
Patients with evidence of another malignancy (exclusive of a skin cancer that requires only local treatment);\r\n* Patients with prior malignancies diagnosed > 5 years ago without evidence of disease are eligible\r\n* Patients with prior malignancy treated < 5 years ago but have a life expectancy of > 5 years for that malignancy are eligible
Prior invasive malignancy of other histology currently requiring treatment
Concurrent active malignancy requiring systemic treatment
Has active secondary malignancy that requires treatment.
Patients with another malignancy within the past 5 years
Undergoing active treatment for a secondary malignancy.
Active malignancy other than the one for which the UCB transplant is being performed within 12 months of enrollment.
Active malignancy besides HNSCC or primary skin basal cell carcinoma; (patients with a concomitant malignancy that has not progressed within 12 months of study entry are eligible)
Subjects with a history of recent (within 28 days) systemic therapy for their underlying malignancy
History of a concurrent or second malignancy, except for specified exceptions in the protocol or any other cancer that has been in complete remission for ? 5 years
Any \currently active\ second malignancy, other than non-melanoma skin cancer. Patients are not considered to have a \currently active\ malignancy, if they have completed therapy and are considered by their physician to be at least less than 30% risk of relapse over next 3 months.
Concomitant treatment with chemotherapeutic agents for diseases other than malignancy
Patients with more than one type of active malignancy; an active malignancy is defined as one that is being treated with therapeutic intent and for which survival may be impacted, within 3 years of enrollment
Another current or previous malignancy within 2 years of study entry unless approved by the sponsor
Current or previous other malignancy within 2 years of study entry without sponsor approval
Invasive malignancy or history of invasive malignancy other than disease under study: any other invasive malignancy from which the subject has been disease-free for more than 2 years and, in the opinion of the principal investigator and GSK Medical Monitor, will not affect the evaluation of the effects of this clinical trial treatment on currently targeted malignancy, can be included in this clinical trial; Curatively treated non-melanoma skin cancer and any carcinoma-in-situ.
Cholangiocarcinoma with extra-hepatic metastasis or concurrent non-solid malignancy
the malignancy has been in remission without treatment for ? 5 years prior to enrollment, or
Histological or cytological evidence of malignancy.
Patients with concurrent malignancy; patients with prior or concurrent malignancy will be allowed as long as the treating physician considers it unlikely to impact the clinical outcome of the patient
Patients with known concurrent malignancy
History of another primary malignancy that has not been in remission for 3 years
Histopathologically confirmed diagnosis of a metastatic non-hematologic malignancy.
Subjects being actively treated for a secondary malignancy.
For the hematologic malignancy patients, blood count values cited above do not apply.
Pathologically (histologically or cytologically) proven diagnosis of a non-hematopoietic malignancy other than small cell lung cancer and germ cell malignancy within 5 years of registration; if the original histologic proof of\r\nmalignancy is greater than 5 years, then pathological confirmation is required (e.g. from extra- or intra-cranial disease)
History of another malignancy within 2 years prior to starting study treatment
Prior history of other malignancy except:
Other currently active malignancy
History of other primary malignancy requiring systemic treatment within 6 months of protocol enrollment; patients must not have another active malignancy requiring treatment; patients must not be receiving chemotherapy or immunotherapy for another cancer
Active concurrent malignancy (except skin cancer)
Any malignancy within 5 years prior to Cycle 1, Day 1
Other active malignancy
RECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Patients have a history of any other malignancy
NON-PROGRESSED DIPG (STRATUM 2): Patients have a history of any other malignancy
Patients must not have another, non-breast, active malignancy that requires treatment
Has a known additional malignancy that is progressing or requires active treatment.
Previous diagnosis of another malignancy with any evidence of residual disease
History (within 2 years prior to first study drug administration) of another malignancy unless the malignancy was treated with curative intent and likelihood of relapse is small (<5% in 2 years in the judgment of the investigator).
Patients with a \currently active\ second malignancy other than non-melanoma skin cancers are not eligible; patients are not considered to have a \currently active\ malignancy if they have completed anti-cancer therapy and are considered by their physician to be at less than 30% risk of relapse
Patients must have primary brain malignancy (histologically confirmed by surgical specimen or cerebral spinal fluid [CSF] cytology), or metastatic brain malignancy; if the patient has metastatic brain malignancy, there must be a histologic pathology report confirming the primary site of the cancer, as well as one of the following: confirmation by surgical specimen, CSF cytology, elevated tumor markers, or clinical evidence of CNS involvement
Other active primary malignancy requiring treatment or limiting survival to =< 2 years prior to registration
Concurrent active malignancy under treatment.
Patients with a \currently active\ second malignancy other than non-melanoma skin cancer are excluded; (patients are not considered to have a \currently active\ malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse)
Confirmed diagnosis of advanced malignancy:
Have a second primary malignancy that, in the judgment of the investigator and sponsor, may affect the interpretation of results.
Second malignancy currently requiring active therapy.
Other active malignancy that requires therapy
Cerebral/meningeal disease related to the underlying malignancy, unless definitively treated.
Lung disease unrelated to underlying malignancy.
Prior radiotherapy to the ipsilateral chest wall for any malignancy.
Active and uncontrolled relapse of malignancy
Any other current malignancy
Any prior history of other hematologic malignancy besides FL or myelodysplasia
Confirmed malignancy.
Presence of an active secondary malignancy.
Patients with a completely treated prior malignancy with no evidence of disease for ?3 years are eligible
Uncontrolled concurrent malignancy
Patients with active secondary malignancy will not be eligible
Active malignancy other than SCLC within the previous 5 years
A second invasive malignancy requiring active treatment
Advanced solid tumor malignancy
Known past or current malignancy other than inclusion diagnosis, except for:
Current (within last 3 months) use of radiation for breast or other malignancy
No concurrent malignancy with a life expectancy of less than two years, or one that requires ongoing chemotherapeutic intervention at screening
Subject has concomitant active second malignancies unless remission was achieved at least 3 years prior to study entry and subject is no longer on therapy for the malignancy.
Patients with prior invasive malignancy within two years of enrollment are excluded
Second primary malignancy
Prior treatment of any kind for this malignancy
Does not have any other active malignancy other than the one for which this transplant is indicated
No other known active secondary primary malignancy
Any “currently active” second malignancy, other than non-melanoma skin cancer; patients are not considered to have a \currently active” malignancy, if they have completed therapy and are considered by their physician to be at least less than 30% risk of relapse over next year
Patient has any other active malignancy other than the one for which HCT is indicated
History of other malignancy that could affect compliance with the protocol or interpretation of results
Being actively treated for another concurrent malignancy
Any other current malignancy
History of another malignancy, some exceptions may apply.
History of another active malignancy within the past 5 years, or any malignancy with a confirmed activating RAS mutation. The prospective RAS mutation testing is not required, however, if results of previous RAS testing are known, they must be used in assessing eligibility. Subjects with a history of completely resected non-melanoma skin cancer are eligible.
Another active concurrent malignancy.
Active and uncontrolled relapse of malignancy
No active second malignancy
Leptomeningeal disease as the only manifestation of the current malignancy
History of documented adrenal dysfunction not due to malignancy.
History of another malignancy in the previous 5 years, unless cured by surgery alone and continuously disease-free
Second primary malignancy that has not been in remission for more than 3 years
Currently active other malignancy excluding controlled non-melanoma skin cancer. Patients are considered NOT to have \currently active\ malignancy if they have completed any necessary therapy and are considered by their physician to be at less than 30% risk of relapse.
Patients with active secondary malignancy will not be eligible unless approved by the principal investigator (PI)
Patients with an active second malignancy within the last 2 years with the exception of:
Any prior or current malignancy or myeloproliferative or immunodeficiency disorder.
Any prior or current malignancy or myeloproliferative disorder.
Free of metastatic malignancy (other than MDS) for ?2 years
No history of any hematopoietic malignancy
Receiving any other standard treatment for their hematologic malignancy.
Patients receiving active treatment or intervention for any other malignancy or patients who, at the Investigator's discretion, may require active treatment or intervention for any other malignancy within 8 months of starting study treatment.
Other current malignancy than the disease under study
History of documented adrenal dysfunction not due to malignancy.
Malignancy OTHER than the BRAF mutant malignancy under study.
Uncontrolled concurrent malignancy that would limit assessment of efficacy of cabozantinib
Other active concomitant malignancy that warrants systemic therapy
Other active concomitant malignancy that warrants systemic therapy
Concurrent history of malignancy other than cervical cancer within 3 years of first planned dose of REGN2810, except for tumors with negligible risk of metastasis
Concurrent malignancy or malignancy within 3 years prior to start of study treatment
Does not have any other active malignancy other than the one for which this transplant is indicated
Patients who have a history of primary malignancy other than that being treated in this study, and currently requires active clinical intervention.
Patient has another concurrent invasive malignancy (aside from the malignancy for which the patient has received therapy for on the parental protocol).
Leptomeningeal disease as the only manifestation of the current malignancy
Second malignancy within the past 3 years except:
History of another malignancy within the previous 5 years;
Subjects with a history of prior malignancy active within the previous 2 years except for locally curable cancers that have been apparently cured
Malignancy other than NSCLC within 5 years prior to randomization and evidence of any other disease that contraindicates the use of an investigational or SOC drug
Any other malignancy that requires active treatment
History of another primary malignancy that has not been in remission for at least 3 years
Known transformation to an aggressive B-cell malignancy.
Have second primary malignancy that may affect the interpretation of results.
Have a second primary malignancy that in the judgment of the investigator and sponsor may affect the interpretation of results
Histologic or cytologic confirmation of a solid malignancy
Leptomeningeal disease as the only manifestation of the current malignancy
Actively treated for a second malignancy
Untreated second malignancy
History of any other malignancy requiring active treatment
No other currently active malignancy.
History of any hematopoietic malignancy
Concurrent active malignancy.
The patient has (or has had) previous or concomitant malignancies, except effectively treated malignancy that is considered by the investigator highly likely to have been cured.
Other active malignancy.
Known diagnosis of second malignancy within the past 5 years
Other malignancy requiring active treatment at time of study entry
Presence of another concurrent malignancy requiring treatment
Previous or concurrent malignancy is not an exclusion provided that the other malignancy is considered under control and target lesions from melanoma are clearly defined for response assessment
Evidence of other concurrent active malignancy
Patients with a pathologic diagnosis of malignancy
A diagnosis of any hematologic or solid malignancy
History of a primary bone malignancy involving the lumbar spine
With a hematological malignancy
Patients must not have other active concurrent malignancy
Current severe active systemic disease including active concurrent malignancy
Has history of a diagnosed and/or treated hematologic or primary solid tumor malignancy, unless in remission for at least 5 years prior to randomization
Subject has other prior malignancy that is not in complete remission.
Untreated active, or inappropriately/inadequately treated breast malignancy, without surgical treatment
Invasive malignancy or history of invasive malignancy other than disease under study within the last two years except: Any other invasive malignancy for which the subject was definitively treated, has been disease-free for <=2 years and in the opinion of the principal investigator and GSK Medical Monitor will not affect the evaluation of the effects of the study treatment on the currently targeted malignancy, may be included in this clinical trial; and curatively treated non-melanoma skin cancer.
Are undergoing cancer treatment for another malignancy
Patients may have a history of other prior malignancy
Recurrent or progressive malignancy requiring anti-cancer therapy
Metastatic malignancy of any kind
Metastatic malignancy of any kind
Patients with hematologic malignancy receiving care (chemotherapy, immunotherapy, targeted agents, bone marrow transplant, or other) for their hematologic malignancy at the Ohio State University
Patients without a diagnosis of a gynecologic malignancy
Recurrent or progressive malignancy requiring anticancer treatment
Secondary malignancy
Progressive malignancy
Diagnosis of a hormone responsive malignancy
History of previous systemic chemotherapy unless given curatively for other malignancy now > 5 years without evidence of recurrence
Presence of any other concurrent, actively treated malignancy
Presence of a concurrent, actively treated malignancy
Concurrent malignancy or metastatic malignancy of any kind
Patients with evidence of persistent or active malignancy
Concurrent or history of malignancy
Diagnosis of malignancy treated with chemotherapy and/or radiation therapy at Seattle Children's Hospital (SCH)\r\n* New diagnosis of malignancy within 1-10 weeks of enrollment\r\n* New diagnosis of recurrent disease (after initial remission) or refractory disease at any time during therapy
There is histocytological confirmation of pleural malignancy
No concurrent second malignancy requiring systemic therapy
Participants must not have any other concurrent malignancy
Concurrent malignancy. Participants with carcinoma in situ of any origin and participants with prior malignancies in remission may be eligible with sponsor approval.
Participants has a history of hematological malignancy within the last 5 years prior to study entry
Patient has an active concurrent malignancy requiring active therapy
Any prior invasive malignancy within 5 years before randomization
Pathologically (histologically or cytologically) proven diagnosis of a non-hematopoietic malignancy other than small cell lung cancer and germ cell malignancy within 5 years of registration; if the original histologic proof of malignancy is greater than 5 years, then pathological confirmation is required (e.g. from extra- or intra-cranial disease)
Another active malignancy
Malignancy with bone instability
Patients with active malignancy; patient undergoing active treatment for malignancy in the adjuvant setting are eligible; treatment can include chemotherapy, targeted therapy or anti-hormonal therapy
Patients have a concurrent malignancy
Subjects who have previously completed primary treatment for a gynecologic malignancy
Active and uncontrolled relapse of malignancy
Patients with evidence of recurrent malignancy
Active hematologic malignancy (cancer that begins in blood-forming tissue, such as leukemia or lymphoma)
Active malignancy other than ovarian cancer
Active malignancy, metastatic disease, or anyone undergoing treatment for malignancy
Concurrent malignancy requiring active treatment with chemotherapy, immunotherapy, or radiation
Women with an active malignancy
Patients who have received chemotherapy for a malignancy in the past 5 years
RPFNA criteria:\r\n* Cells suspicious for malignancy
Metastatic malignancy of any kind
Other current malignancy or metastatic malignancy of any kind
Patients with a relapsed and/or refractory underlying hematologic malignancy
Subjects may have a history of prior malignancy except for esophageal adenocarcinoma
Concurrent malignancy or metastatic malignancy of any kind
Patients with a \currently active\ second malignancy other than non-melanoma skin or superficial urothelial cancers are not eligible; patients are not considered to have a \currently active\ malignancy if they have completed therapy and are now considered without evidence of disease for 2 years
Any other current or previous malignancy
Another malignancy within 3 years
Non-hematologic malignancy within prior three (3) years.
History of malignancy, including prior SCCHN primary tumors within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death
Currently receiving treatment for any malignancy
Subject has had any other prior invasive malignancy, unless disease-free for a minimum of 3 years.
Subject receiving radiotherapy alone as treatment for his/her haematologic malignancy.
Inflammatory breast malignancy
history of any other primary malignancy diagnosed within the past 5 years
Patient must not have another active (within past 3 years) or concurrent malignancy
EXCLUSION - HEALTHY VOLUNTEERS: Prior or current malignancy
Malignancy other than current disease under study
Relapsed/persistent malignancy
Any other current or previous malignancy within the past 5 years
Malignancy consistent with a neuroendocrine histology
Patient has an active malignancy of metastatic potential other than the known NE tumor for the past 3 years
Subjects must not have been treated with chemotherapy or radiation for another malignancy within the preceding 6 months
History of a prior malignancy within past 5 years are excluded unless they have been disease free for 3 or more years
Prior systemic chemotherapy for rectal cancer; prior chemotherapy for another malignancy is allowable as long as it has been > 2 years since completion of therapy for previous malignancy
Prior systemic chemotherapy for esophageal cancer; prior chemotherapy for another malignancy is allowable as long as it has been > 2 years since completion of therapy for previous malignancy
Concurrent malignancy other than skin cancer
Individuals with a history of a different malignancy are ineligible except for the following circumstances; individuals with a history of other malignancies are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy
Has history of other active malignancy within 3 years prior to enrollment, except:
Subjects must not have another active invasive malignancy, with the following exceptions and notes:
History of malignancy that is in complete remission after treatment with curative intent is allowed.
Has a second concurrent active primary malignancy such as solid tumor or lymphoma under active treatment
Evidence of active malignancy at the time of HCT or at any time since the HCT.
History of malignancy (other than the disease that required the HCT) within 5 years prior to screening.
Second primary invasive malignancy that has not been in remission for greater than 2 years.
Has a history of a previous additional malignancy unless potentially curative treatment has been completed with no evidence of malignancy for 5 years
Patients who have already started treatment for the current malignancy
Women with a history of a prior malignancy
Diagnosis of malignant liver tumor; (pathological diagnosis of malignancy or at least one liver lesion seen on imaging that is suspicious for malignancy)
Presence of synchronous malignancy for which the patient is currently receiving active treatment
Active other malignancy requiring treatment that would interfere with the assessments of this study
Current or recent treatment for any malignancy within the last one year, which may affect biomarkers
Evidence of other active malignancy requiring treatment
Have a second primary malignancy or any history in any time frame of a prior malignancy.
Patients may have had a prior malignancy
Presence of concurrent non-solid malignancy
Scheduled for a lumpectomy for a breast malignancy.
Criteria 5, History of other malignancy within the past 5 years prior to enrollment with some exceptions, as outlined in the protocol.
A working diagnosis of malignancy in the liver, brain, H&N, or pelvis
Prior malignancy, active within the last 3 years, except for locally curable cancers which have been apparently cured
Prior or concurrent malignancy, except the following:
History of other malignancy within the past 3 years
At least ? 2 prior treatment regimens for the underlying malignancy
Other malignancy with life expectancy < 1 year due to the other malignancy
History of other malignancy within the past 5 years with the following exception: . malignancy treated with curative intent and with no known active disease present and has not received chemotherapy for > 5 years before enrollment and felt to be at low risk for recurrence by the treating physician.
Are currently receiving other medications or radiation intended for the treatment of their malignancy
Patients with a “currently active” second malignancy other than non-melanoma skin cancers; patients are not considered to have a “currently active” malignancy if they have completed therapy and are free of disease for >= 3 years
History of gynecologic malignancy that is estrogen dependent
